Pyoderma is the most frequent reason for antibiotic use in dogs. This condition is easily diagnosed since it is visible, but the treatment is challenging because of bacterial resistance.

InflaRx’s vilobelimab met the bar for futility in a Phase III trial for the rare skin disease pyoderma gangrenosum.

Of the ulcers in the 64 patients treated for pyoderma gangrenosum, it was clear that those in 23 patients (36 percent) did not respond to treatment directed at pyoderma gangrenosum, those in 8 (12 ...

InflaRx ends its Phase 3 trial of vilobelimab in pyoderma gangrenosum and shifts focus to INF904 amid efforts to extend its ...

In general, the sicker you are with other conditions, the worse your pyoderma gangrenosum is likely to be. Usually, people recover with treatment. But the ulcers can last for months and leave ...

Treatment of PG is currently limited to immune-suppressing drugs and antibiotics to treat complicating infections, and, in ...

in pyoderma gangrenosum (PG) and severe COVID-19. Vilobelimab has been granted orphan drug designation for the treatment of PG by both the Food and Drug Administration (FDA) in the US and the ...

Ulcerative pyoderma gangrenosum is a rare disease with no current treatment. Vilobelimab has been granted orphan drug and fast track designations by the FDA. InflaRx has initiated a phase 3 study ...

Pyoderma gangrenosum (PG) is a rare autoimmune dermatosis considered to be one of the possible cutaneous extraintestinal manifestations of inflammatory bowel diseases (IBD). PG exhibits a rapid ...

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to ...

US Food and Drug Administration awards Fast Track designation for the treatment of ulcerative pyoderma gangrenosum Fast track follows recently reported orphan drug designation by both US FDA and ...

Some cases traditionally identified as pyoderma gangrenosum (PG ... that a notable number of patients were refractory to treatment, with more than 1 in 3 (41.4%) patients having no response ...